Goldman Sachs Reiterates Neutral Rating on Ionis Pharmaceuticals, Inc. (IONS)
Rating Change Goldman Sachs analysts reiterated a Neutral rating on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on June 25, 2026. Market Context Ionis Pharmaceuticals, Inc.
Read more
